FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

ngton, D.C. 20549	OMB A

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

1. Name and Address of Reporting Person* KELER TIBOR				2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]							Chec	k all applic Directo	cable)	g Pers	son(s) to Iss 10% Ov Other (s	/ner			
(Last)	`	irst) ERAPEUTICS,	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023						X	below)		E VI	below)	респу		
53 FRONTAGE ROAD, SUITE 220					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person						
(Street) HAMPT	ON N	J	08827											X		led by More		orting Perso	- 1
(City)	(S	tate)	(Zip)			Rule 10b5-1(c) Transaction Indication													
								Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.											
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (In:	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)				3, 4 and Securit		ies Fo ially (D) Following (I)		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A) or (D)		е	Transaction(s) (Instr. 3 and 4)			(111301. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Courity or Exercise (Month/Day/Year) if any		ransact	ansaction of ode (Instr. Derivative			Expiration Date A (Month/Day/Year) S U D			7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)		S	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares	er					
Incentive Stock Option (right to buy) ⁽¹⁾	\$36.87	06/15/2023 ⁽¹⁾			A		92,000		06/15/2024 ⁽²	00	6/15/2033	Common Stock	92,00	00	\$0	92,000		D	

Explanation of Responses:

- 1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
- 2.25% vest on June 15,2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

/s/ Samuel B. Martin, attorney-06/20/2023 in-fact for Tibor Keler

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.